JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB219445

Recombinant Human CD229 protein (His tag C-Terminus)

Recombinant Human CD229 protein (His tag C-Terminus)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human CD229 protein (His tag C-Terminus) is a Human Fragment protein, in the 48 to 454 aa range, expressed in Baculovirus infected insect cells, with >90%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE.

別名を表示する

CD229, CDABP0070, LY9, T-lymphocyte surface antigen Ly-9, Cell surface molecule Ly-9, Lymphocyte antigen 9, SLAM family member 3, Signaling lymphocytic activation molecule 3, SLAMF3

1 Images
SDS-PAGE - Recombinant Human CD229 protein (His tag) (AB219445)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human CD229 protein (His tag) (AB219445)

15% SDS-PAGE analysis of ab219445 (3μg).

Key facts

精製度

>90% SDS-PAGE

エンドトキシンレベル

< 1 EU/µg

発現系

Baculovirus infected insect cells

タグ

His tag C-Terminus

アプリケーション

SDS-PAGE

applications

生物活性

No

アクセッション番号

Q9HBG7

アニマルフリー

No

キャリアフリー

No

種

Human

バッファー組成

pH: 7.4 Constituents: PBS, 10% Glycerol (glycerin, glycerine)

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column
style
left-column

配列情報

[{"sequence":"ADLKDSAPTVVSGILGGSVTLPLNISVDTEIENVIWIGPKNALAFARPKENVTIMVKSYLGRLDITKWSYSLCISNLTLNDAGSYKAQINQRNFEVTTEEEFTLFVYEQLQEPQVTMKSVKVSENFSCNITLMCSVKGAEKSVLYSWTPREPHASESNGGSILTVSRTPCDPDLPYICTAQNPVSQRSSLPVHVGQFCTDPGASRGGTTGETVVGVLGEPVTLPLALPACRDTEKVVWLFNTSIISKEREEAATADPLIKSRDPYKNRVWVSSQDCSLKISQLKIEDAGPYHAYVCSEASSVTSMTHVTLLIYRRLRKPKITWSLRHSEDGICRISLTCSVEDGGNTVMYTWTPLQKEAVVSQGESHLNVSWRSSENHPNLTCTASNPVSRSSHQFLSENICSGPERNTKHHHHHH","proteinLength":"Fragment","predictedMolecularWeight":"45.9 kDa","actualMolecularWeight":null,"aminoAcidEnd":454,"aminoAcidStart":48,"nature":"Recombinant","expressionSystem":"Baculovirus infected insect cells","accessionNumber":"Q9HBG7","tags":[{"tag":"His","terminus":"C-Terminus"}]}]
style
left-column

出荷温度及び保存条件

出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle
False
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

CD229 also known as SLAMF3 or Ly9 is a transmembrane protein that weighs approximately 80 kDa. This protein belongs to the CD2 subset of the immunoglobulin superfamily. You can find high expression of CD229 in various lymphoid tissues such as the spleen thymus and peripheral blood lymphocytes. Its expression is notably high in T cells B cells and natural killer (NK) cells. As a homophilic receptor CD229 aids in cell-cell adhesion playing an essential role in immune response regulation among lymphocytes.
Biological function summary

CD229 influences signaling within immune cells. It functions as a mediator of adhesion and activation signaling pathways. CD229 does not act alone and often works as part of a receptor complex that may include CD48 and other members of the SLAM family. Besides its role in cellular adhesion CD229 participates in balancing immune activation and immune tolerance demonstrating its importance in developing and maintaining a robust immune response.

Pathways

CD229 participates in the adaptive immune signaling pathways. It links with other signaling proteins such as SAP (SLAM-associated protein) a critical modulator of downstream signaling cascades. SAP interacts with SLAM-family receptors including CD229 to regulate T and B cell activation and function. The involvement of CD229 in various immune signaling pathways positions it as a significant player in the broader context of cellular communication and response within the immune system.

CD229's aberrant expression or dysfunction links to autoimmune diseases such as systemic lupus erythematosus (SLE) and certain hematological malignancies. Altered CD229 expression has been observed in association with SLE where it may contribute to dysregulated immune responses. In hematological cancers CD229 overexpression or mutations can disrupt immune cell regulation promoting tumor progression. CD229 may interact with other SLAM-family proteins like CD244 which have implications in disease pathology and can be targets for therapeutic interventions.
style
left-column

製品の性状

製品の状態

Liquid

補足情報

Affinity purified

style
left-column

一般的な情報

機能

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A (PubMed : 22184727). Promotes recruitment of RORC to the IL-17 promoter (PubMed : 22989874). May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4(+) T-cells. May negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells (By similarity).

style
left-column

製品プロトコール

style
left-column

ターゲットの情報

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A (PubMed : 22184727). Promotes recruitment of RORC to the IL-17 promoter (PubMed : 22989874). May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4(+) T-cells. May negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells (By similarity).
See full target information LY9
style
left-column
style
left-column
style
right-column

組合せ製品

Proteins & Peptides

AB288799

Recombinant Human VCAM1 protein (Active)

Premium Bioactive

Biological Activity - Recombinant Human VCAM1 protein (Active) (AB288799)

  • 0
  • 0
Primary Antibodies

AB252931

Anti-CD229 antibody [EPR22611-91]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD229 antibody [EPR22611-91] (AB252931)

  • 5
  • 2
Proteins & Peptides

AB219428

Recombinant Human SLAMF6 protein (His tag C-Terminus)

SDS-PAGE - Recombinant Human SLAMF6 protein (His tag) (AB219428)

  • 0
  • 0
Proteins & Peptides

AB276727

Recombinant Human CD90 / Thy1 protein (His tag)

SDS-PAGE - Recombinant Human CD90 / Thy1 protein (His tag) (AB276727)

  • 0
  • 0

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com